Chronic Condition Management

Strong evidence supports removal of restrictions to direct-acting antiviral therapy based on recent drug use.

Shared diabetes services may be essential to successfully treating patients with this disease without overburdening physicians.

Two studies show these kidneys could be valuable resource for patients in need

New approaches are needed for physicians to engage young people who inject drugs

An urgent call to action to treat combined epidemics

Glucose tolerance is an independent predictor of overall mortality and hepatic decompensation in patients with HCV cirrhosis.

Physicians share the benefits of having nurse practitioners available at their practices to aid both patients and fellow healthcare clinicians.

Ledipasvir/sofosbuvir is safe and effective for hepatitis C virus patients who fail on simeprevir/ sofosbuvir.

Real-world study shows efficacy of sofosbuvir/velpatasvir for 12 weeks

Sofosbuvir-velpatasvir-voxilaprevir provides salvage therapy for NS5A failures

Despite the availability of new, highly successful direct-acting antiviral (DAA) regimens, more than one third of chronic hepatitis C (HCV) patients are denied access to treatment by their insurance provider, according to a new study.

For the White House to meet its goals on stopping the nation’s opioid crisis, there are some practical steps to put in place first.

Treatment with a combination of ledipasvir and sofosbuvir can lead to large economic gains.

Clinicians need to carefully plan treatment when prescribing DAA therapy for patients infected with hepatitis C virus who have hepatocellular carcinoma.

All hepatitis C virus genotypes respond to therapy

Recipients of hepatitis C-infected kidneys treated with direct-acting antiviral agents are disease-free one year post-transplant.

More patients could take advantage of shorter direct-acting antiviral treatment duration.

Females, Hispanics screened less often for highly curable infection.

With the advent of new direct-acting antiviral agents, HCV treatment has greatly improved, making identification of infected individuals even more imperative.

More effort needed to integrate screening with follow-up care to prevent spread of the virus.

Less than 10% of eligible COPD patients were referred to pulmonary rehabilitation programs, according to a new UK study.

Long-thought to be primarily caused by smoking and other exposures, scientists now believe that congenital changes to lung tissues with a genetic link may also be to blame.

Hispanic and Asian patients have a higher risk of cirrhosis and liver cancer, but direct-antiviral treatment eliminates ethnic disparities.

Those using illicit drugs and co-infected with HIV and hepatitis C are willing to use direct-acting anti-viral agents, says a new study.

Study: Certain bronchodilators may lead to an increased risk of cardiovascular disease in COPD patients at onset of starting therapy.